NC
RCKT icon

NinePointTwo Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

NinePointTwo Capital’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,936
Closed -$237K – 309
2023
Q2 		$237K Hold
11,936
– – 0.09% 157
2023
Q1 		$204K Buy
+11,936
New +$234K 0.08% 219

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

NinePointTwo Capital's RCKT Position: Q3 2023 in Review

NinePointTwo Capital sold out of Rocket Pharmaceuticals (RCKT) in Q3 2023, closing a stake of 11,936 shares — an estimated $237K sold.

NinePointTwo Capital first reported a position in RCKT in Q1 2023 and held it in 2 quarters. The position peaked at $237K in Q2 2023. 175 funds tracked by Wall St. Rank hold RCKT as of Q3 2023.

  • NinePointTwo Capital reported no remaining Rocket Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • NinePointTwo Capital sold 11,936 Rocket Pharmaceuticals shares in Q3 2023, an estimated $237K.
  • NinePointTwo Capital first reported a position in Rocket Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • NinePointTwo Capital's Rocket Pharmaceuticals position peaked at $237K in Q2 2023.
  • 175 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2023.

Based on NinePointTwo Capital's 13F filing for Q3 2023, filed 14 Nov 2023.